MAP
PCVX icon

Moody Aldrich Partners’s Vaxcyte PCVX Stock Holding History

Moody Aldrich Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,157
Closed -$1.93M – 194
2025
Q1 		$1.93M Sell
51,157
-1,529
-3% -$122K 0.4% 87
2024
Q4 		$4.31M Sell
52,686
-1,483
-3% -$147K 0.8% 57
2024
Q3 		$6.19M Sell
54,169
-46,117
-46% -$4.16M 1.13% 32
2024
Q2 		$7.57M Sell
100,286
-18,316
-15% -$1.25M 1.48% 8
2024
Q1 		$8.1M Sell
118,602
-29,325
-20% -$2.03M 1.38% 14
2023
Q4 		$9.29M Buy
147,927
+7,757
+6% +$403K 1.67% 5
2023
Q3 		$7.15M Buy
140,170
+115,505
+468% +$5.7M 1.35% 19
2023
Q2 		$1.23M Buy
+24,665
New +$1.17M 0.24% 111

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Moody Aldrich Partners's PCVX Position: Q2 2025 in Review

Moody Aldrich Partners sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 51,157 shares — an estimated $1.93M sold.

Moody Aldrich Partners first reported a position in PCVX in Q2 2023 and held it in 8 quarters. The position peaked at $9.29M in Q4 2023. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Moody Aldrich Partners reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Moody Aldrich Partners sold 51,157 Vaxcyte shares in Q2 2025, an estimated $1.93M.
  • Moody Aldrich Partners first reported a position in Vaxcyte in Q2 2023 and held it in 8 quarters.
  • Moody Aldrich Partners's Vaxcyte position peaked at $9.29M in Q4 2023.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Moody Aldrich Partners's 13F filing for Q2 2025, filed 4 Aug 2025.